Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

Insiders have been trading these 5 stocks: ((MDGL)), ((CLNN)), ((COR)), ((SQNS)) and ((FOLD)). Here is a breakdown of their recent trades and their value.

Director trading at Madrigal Pharmaceuticals has drawn attention, as Director Rebecca Taub recently sold 2,238 shares of Madrigal Pharmaceuticals stock in a transaction valued at $1,098,343, while GC Shannon T Kelley sold an additional 263 shares for $129,072. Together, these insider sales highlight over $1.2 million in stock being moved out of executive hands, a detail closely watched by investors trying to gauge sentiment at the company. The combination of a sizable sale by a director and a smaller but still notable transaction by the general counsel provides a snapshot of how key insiders are repositioning their holdings in Madrigal Pharmaceuticals.

Clene has seen substantial exit activity from a former major shareholder, with Exit Form 4 filings revealing that former 10% owner Chidozie Ugwumba has been significantly reducing his stake. In one transaction, Ugwumba sold 32,474 shares of Clene stock for $161,519, followed by another sale of 18,221 shares worth $96,657. These two moves together represent the liquidation of 50,695 shares and a total value of $258,176, underscoring a decisive shift away from the position by a once-large owner and adding an important data point for investors monitoring ownership changes at Clene.

At Cencora, insider activity has centered on the top executive, with President & CEO Robert Mauch executing a sizable sale that may catch the eye of market watchers. Mauch sold 5,096 shares of Cencora stock in a single transaction worth $1,807,704, signaling a meaningful cash-out by the company’s highest-ranking officer. While such sales can be driven by a variety of personal or financial planning reasons, the nearly $1.8 million transaction will likely be scrutinized as investors assess how leadership is managing its equity exposure to Cencora.

In contrast to the insider selling seen elsewhere, Sequans Communications S A has attracted notable insider buying by a significant shareholder, suggesting a vote of confidence in the company’s prospects. Significant shareholder Daniel Asher purchased 39,831 shares of Sequans Communications S A stock in one transaction for $225,045, then added another 42,260 shares in a separate purchase worth $222,425. These two buys total 82,091 shares and $447,470 in fresh capital, reinforcing the perception that Asher sees value at current price levels and is willing to commit substantial funds to increase his stake in Sequans Communications S A.

Amicus Therapeutics has also joined the lineup of companies with noteworthy insider activity, as President & CEO Bradley Campbell recently executed a large stock sale. Campbell sold 75,000 shares of Amicus stock in a transaction valued at $1,072,500, converting a significant equity position into cash. The sheer size of the 75,000-share sale, surpassing the million-dollar mark in value, will be watched closely by shareholders who track executive transactions for insight into management’s confidence in Amicus’s future performance and stock valuation.